Cargando…
Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186065/ https://www.ncbi.nlm.nih.gov/pubmed/34103038 http://dx.doi.org/10.1186/s12890-021-01559-7 |
| _version_ | 1783704887051157504 |
|---|---|
| author | Huang, Tang-Hsiu Kuo, Chin-Wei Chen, Chian-Wei Tseng, Yau-Lin Wu, Chao-Liang Lin, Sheng-Hsiang |
| author_facet | Huang, Tang-Hsiu Kuo, Chin-Wei Chen, Chian-Wei Tseng, Yau-Lin Wu, Chao-Liang Lin, Sheng-Hsiang |
| author_sort | Huang, Tang-Hsiu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8186065 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81860652021-06-10 Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study Huang, Tang-Hsiu Kuo, Chin-Wei Chen, Chian-Wei Tseng, Yau-Lin Wu, Chao-Liang Lin, Sheng-Hsiang BMC Pulm Med Correction BioMed Central 2021-06-08 /pmc/articles/PMC8186065/ /pubmed/34103038 http://dx.doi.org/10.1186/s12890-021-01559-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Huang, Tang-Hsiu Kuo, Chin-Wei Chen, Chian-Wei Tseng, Yau-Lin Wu, Chao-Liang Lin, Sheng-Hsiang Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title | Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title_full | Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title_fullStr | Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title_full_unstemmed | Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title_short | Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| title_sort | correction to: baseline plasma kl-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186065/ https://www.ncbi.nlm.nih.gov/pubmed/34103038 http://dx.doi.org/10.1186/s12890-021-01559-7 |
| work_keys_str_mv | AT huangtanghsiu correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy AT kuochinwei correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy AT chenchianwei correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy AT tsengyaulin correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy AT wuchaoliang correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy AT linshenghsiang correctiontobaselineplasmakl6levelpredictsadverseoutcomesinpatientswithidiopathicpulmonaryfibrosisreceivingnintedanibaretrospectiverealworldcohortstudy |